Q2 26 EPS
$-0.81
BEAT +9.81%
Est. $-0.90
Q2 26 Revenue
$15.0M
BEAT +8.99%
Est. $13.8M
vs S&P Since Q2 26
+17.2%
BEATING MARKET
NTLA +17.5% vs S&P +0.2%
Market Reaction
Did NTLA Beat Earnings? Q2 2026 Results
Intellia Therapeutics delivered a beat on both the top and bottom lines in Q1 2026, extending its EPS beat streak to four consecutive quarters as the gene editing company navigated a pivotal transition toward commercialization. The company posted a l… Read more Intellia Therapeutics delivered a beat on both the top and bottom lines in Q1 2026, extending its EPS beat streak to four consecutive quarters as the gene editing company navigated a pivotal transition toward commercialization. The company posted a loss of $0.81 per share, ahead of the $0.90 consensus estimate by 9.81%, while revenue of $15.05 million cleared expectations by 8.99%, even as collaboration revenue slipped 9.5% year-over-year from $16.63 million. The primary financial driver was a sharp pullback in R&D spending to $80.74 million from $108.43 million a year ago, reflecting lower costs for research materials and contracted services, which helped narrow the net loss to $96.23 million from $114.33 million. The quarter's defining moment, however, was clinical: Phase 3 HAELO topline data showed lonvo-z reduced hereditary angioedema attacks by 87% versus placebo, prompting a rolling BLA submission with the FDA and a targeted U.S. Launch in the first half of 2027. With cash of $517.25 million supplemented by an April equity raise of approximately $207 million, management expects to fund operations into 2028, though some analysts have flagged dilution concerns from that offering.
Key Takeaways
- • Reduced R&D expenses due to lower costs for research materials, contracted services, employee-related expenses, and stock-based compensation
- • Increased G&A expenses from commercial infrastructure buildout and higher legal expenses ahead of lonvo-z launch
NTLA Forward Guidance & Outlook
Intellia expects to complete its BLA submission for lonvo-z in the second half of 2026, targeting a U.S. commercial launch in the first half of 2027. The company plans to complete patient enrollment in MAGNITUDE-2 (nex-z for ATTRv-PN) in the second half of 2026. Including proceeds from an April 2026 underwritten public offering of approximately $207 million in gross proceeds, existing cash resources are expected to fund operations at least into 2028, well beyond the anticipated lonvo-z U.S. launch, excluding potential commercial revenues.
NTLA YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
NTLA Revenue by Segment
With YoY comparisons, source: SEC Filings
“It has been a remarkable start to 2026 for Intellia. With lonvo-z, we achieved a historic milestone by presenting the world's first Phase 3 data for an in vivo gene editing candidate and initiated a rolling BLA submission as we seek to provide a highly differentiated one-time treatment option to people living with HAE. We also recently resumed patient screening for both of our Phase 3 clinical trials in ATTR and strengthened our balance sheet with an underwritten public offering. We look forward to achieving additional important milestones during the remainder of the year.”
— John Leonard, Q2 2026 Earnings Press Release
NTLA Earnings Trends
NTLA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NTLA EPS Trend
Earnings per share: estimate vs actual
NTLA Revenue Trend
Quarterly revenue: estimate vs actual
NTLA Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q1 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q4 25 BEAT FY | $-0.96 | $-0.83 | +13.71% | $23.0M | +89.08% |
| FY Full Year | $-4.00 | $-3.81 | +4.75% | $67.7M | +18.53% |
| Q3 25 BEAT | $-0.98 | $-0.92 | +6.49% | $13.8M | -2.41% |
| Q2 25 BEAT | $-1.01 | $-0.98 | +2.51% | $14.2M | +17.12% |
| Q1 25 BEAT | $-1.27 | $-1.10 | +13.46% | $16.6M | +38.72% |
| Q4 24 BEAT FY | $-1.32 | $-1.27 | +3.52% | $12.9M | +58.94% |
| FY Full Year | — | $-5.25 | — | $57.9M | — |